Madrigal licenses Arrowhead's PNPLA3 siRNA for $1bn in MASH push
Madrigal Pharmaceuticals has secured an exclusive global licence to ARO-PNPLA3, a clinical-stage small interfering RNA (siRNA) asset from Arrowhead Pharmaceuticals that targets a key genetic driver of metabolic dysfunction-associated steatohepatitis (MASH). The deal carries a $25 million upfront payment and up to $975 million in milestone payments, plus royalties on net sales — a structure that reflects the competitive intensity now building around genetically stratified MASH therapy.
ARO-PNPLA3 is a GalNAc-conjugated siRNA designed to silence the PNPLA3 gene variant I148M, which disrupts hepatic fat processing and is strongly associated with fibrosis progression, cirrhosis, and hepatocellular carcinoma. Roughly 30% of MASH patients with moderate-to-advanced fibrosis (F2–F3) carry two copies of the variant and are classified as homozygous — the population in which the asset has shown its clearest signal to date. The variant is particularly prevalent in Hispanic and Latino populations, a group historically under-represented in MASH clinical development.
Phase 1 data
Phase 1 results, published in The New England Journal of Medicine, tested ARO-PNPLA3 in 55 patients with metabolic dysfunction-associated fatty liver disease who were either homozygous or heterozygous I148M carriers; approximately 93% identified as Hispanic or Latino. A single dose at the highest level tested produced a 46% reduction in liver fat content — measured by MRI-PDFF — at 12 weeks in homozygous participants, with reductions observed from six weeks and sustained through at least 24 weeks. No clinically meaningful adverse events were reported. Heterozygous participants showed no liver fat reduction at any dose studied, a finding that defines the intended patient selection strategy. Supportive data from a smaller nine-patient Phase 1 trial in Japan were also reported.
Chief medical officer David Soergel said the company plans to consult the FDA on the design of a Phase 2 combination trial pairing ARO-PNPLA3 with Rezdiffra (resmetirom), Madrigal's approved THR-β agonist and currently the only medicine cleared by both the FDA and European Commission for MASH with moderate-to-advanced fibrosis. The rationale is mechanistic complementarity: Rezdiffra addresses broad metabolic dysregulation, while ARO-PNPLA3 would silence a specific genetic amplifier of disease in a defined sub-population.
Market context and competitive positioning
The MASH landscape has shifted considerably since Rezdiffra's approval in 2024. Several other developers — including those with FGF21 analogues, ACC inhibitors, and pan-PPAR agonists — are advancing combination strategies, and the field is increasingly moving towards biomarker-stratified trial designs. Madrigal's decision to layer a precision-medicine asset onto an already-approved backbone mirrors a playbook seen in oncology, where approved drugs are used as combination anchors to extend commercial relevance and address residual disease in sub-populations.
The PNPLA3 I148M variant is among the most genetically validated targets in hepatology, which reduces some of the target-selection risk inherent in earlier-stage licensing. The Phase 1 dose-response data — particularly the clean separation between homozygous and heterozygous participants — strengthens the case for a genetically selected trial design in Phase 2, and should make FDA alignment on endpoints more tractable.
Madrigal now lists more than ten MASH programmes, including seven siRNA assets, signalling an ambition to own the combination-treatment infrastructure in the indication rather than cede it to larger diversified players. Whether the clinical and commercial logic of such a broad pipeline can be sustained will depend heavily on Phase 2 readouts and the company's ability to finance parallel development tracks as Rezdiffra revenues mature.